Overview
The underrepresentation of diverse populations in clinical trials creates knowledge gaps about the risks and benefits of drugs and devices for the public. To address this discrepancy, CTTI is working to determine the value of including diverse patient populations throughout the entire medical product development lifecycle — from early target identification all the way to data lock and submission.
These recommendations and resources will help stakeholders adopt new organization-level practices that increase diversity in clinical trials, leading to enriched research results that are more relevant for everyone.
Solutions
Search AllRecommendation Summary
Recommendations
Resources
Related Items
- Recording of Virtual Public Workshop Now Available: Enhancing Diversity in Clinical Studies
- Virtual Public Workshop to Enhance Clinical Study Diversity (FDORA)
- How to Measure Progress in Improving Clinical Trial Diversity
- Increasing Diversity in Clinical Trials Recommendations Launch
- CTTI Publication Investigates Organizational Practices to Promote Diversity and Inclusion in Clinical Trials
- Enhancing Diversity and Inclusion in Clinical Trials
- Increasing Diversity in Clinical Trials Expert Meeting
- Advancing the Landscape: Increasing Diversity in Clinical Trials
News
- Recording of Virtual Public Workshop Now Available: Enhancing Diversity in Clinical StudiesA recording for the virtual public workshop to enhance clinical study diversity convened by the U.S. Food and Drug Administration (FDA) and Clinical Trials Transformation Initiative (CTTI), held November 29 ...